In July 2023 the Company entered intoan additional supply agreement with a top tier generic pharmaceutical company in Brazil. In Medipharms Q2 Presentation they mention:
BRAZIL FY’23 market value estimate: $70 million USD million (IQVIA & MediPharm)
• Only Canadian Company with drug product approval in Brazil
• High barrier to entry with each product registration requiring 18 to 32 months
• Partners include large multinational pharmaceutical companies, such as Active Pharmaceutica
https://assets-global.website-files.com/61ba7048400e00d31e087120/64376bc4e5f0df438be8a2dd_2023_MediPharm-Investor-Deck-April2023%20%20Final%20Copy.pdf Is Active Pharmaceutica the top tier partner, as they were acquired in June 2021 by Caldic BM who in turn were taken over by Advent International?
https://www.caldic.com/en/News/Caldic-Latin-America-fully-integrated-and-rebranded-to-further-unlock-value-creation